glp 1 facts The promise and peril of GLP-1 agonists: What we do (and don't) know as of August 2024 Compounded GLP-1 medications are trending
Description
10.1073/pnas.1416598111 23 ButzerJ
2022;34(9):123447.e9
Within the same period, the dispensed prescriptions within the benefit to incident patients with a preexisting diagnosis of obesity without T2DM increased by 270% (4.0 to 14.6%), and 502% for patients with neither obesity nor T2DM (5.3 to 32.1%), and 515% for patients without any of the included diagnoses (4.2 to 25.7%) (see Table 9 in the Appendix)
Decreased risk of anxiety in diabetic patients receiving glucagon-like peptide-1 receptor agonist: a nationwide, population based cohort study
However, in Denmark, medication is subsidized by the government
